Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising stocks with huge upside potential. On November 24, Barclays analyst Gena Wang lowered the firm’s price target on Ultragenyx (RARE) to $50 from $81 and maintained an Overweight rating on the shares. The firm lowered its price target following analysis of the setrusumab COSMIC study, but still maintains an over 70% chance of a positive result. Earlier the same month, Ultragenyx Pharmaceutical reported that it made a total revenue of $ ...